Lyell Immunopharma Inc [NASDAQ: LYEL] stock went on a downward path that fall over -7.21% on Wednesday, amounting to a one-week price decrease of less than -6.36%.
Over the last 12 months, LYEL stock dropped by -46.91%. The one-year Lyell Immunopharma Inc stock forecast points to a potential downside of -3.0. The average equity rating for LYEL stock is currently 3.33, trading closer to a bullish pattern in the stock market.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for the stock reached $287.59 million, with 253.96 million shares outstanding and 125.06 million shares in the current float. Compared to the average trading volume of 1.11M shares, LYEL stock reached a trading volume of 4655258 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Lyell Immunopharma Inc [LYEL]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for LYEL shares is $1.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on LYEL stock is a recommendation set at 3.33. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BofA Securities have made an estimate for Lyell Immunopharma Inc shares, keeping their opinion on the stock as Underperform, with their previous recommendation back on October 30, 2024. While these analysts kept the previous recommendation, H.C. Wainwright dropped their target price from $6 to $1. The new note on the price target was released on June 27, 2024, representing the official price target for Lyell Immunopharma Inc stock. Previously, the target price had yet another drop from $15 to $5, while JP Morgan kept a Neutral rating on LYEL stock. On November 14, 2022, analysts decreased their price target for LYEL shares from 15 to 7.
The Average True Range (ATR) for Lyell Immunopharma Inc is set at 0.13, with the Price to Sales ratio for LYEL stock in the period of the last 12 months amounting to 4793.21. The Price to Book ratio for the last quarter was 0.50, with the Price to Cash per share for the same quarter was set at 1.58.
LYEL Stock Performance Analysis:
Lyell Immunopharma Inc [LYEL] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -6.36. With this latest performance, LYEL shares dropped by -10.43% in over the last four-week period, additionally sinking by -62.68% over the last 6 months – not to mention a drop of -46.91% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for LYEL stock in for the last two-week period is set at 42.49, with the RSI for the last a single of trading hit 38.71, and the three-weeks RSI is set at 43.79 for Lyell Immunopharma Inc [LYEL]. The present Moving Average for the last 50 days of trading for this stock 1.2037, while it was recorded at 1.0900 for the last single week of trading, and 1.8316 for the last 200 days.
Insight into Lyell Immunopharma Inc Fundamentals:
Lyell Immunopharma Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 13.43 and a Current Ratio set at 13.43.
LYEL Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for LYEL. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Lyell Immunopharma Inc go to -7.90%.
Lyell Immunopharma Inc [LYEL] Institutonal Ownership Details
There are presently around $61.65%, or 71.73%% of LYEL stock, in the hands of institutional investors. The top three institutional holders of LYEL stocks are: MWG MANAGEMENT LTD. with ownership of 20.16 million shares, which is approximately 7.9301%. ORLAND PROPERTIES LTD, holding 15.09 million shares of the stock with an approximate value of $$21.89 million in LYEL stocks shares; and ORLAND PROPERTIES LTD, currently with $$19.57 million in LYEL stock with ownership which is approximately 5.3078%.
